• Filter By:
• Specialty
• Source
• Condition
• Cancer
• Infectious Disease
• Drug
• Training
• Management
• Procedure
• Therapy
• Vaccine
• Nutrition
• Country

Hypermetabolic lymphadenopathy following the administration of COVID-19 vaccine and immunotherapy in a lung cancer patient: a case report
CONCLUSION: This case report highlights the importance of lymph node biopsies in lung cancer patients who present with contralateral lymphadenopathy following coronavirus disease 2019 vaccination to rule out tumor recurrence in this deserving patient population.PMID:36434709 | DOI:10.1186/s13256-022-03660-9
Source: Cancer Control - November 26, 2022 Category: Cancer & Oncology Authors: Shreya Tripathy Nathaniel Alvarez Shubham Jaiswal Ryan Williams Munaf Al-Khadimi Sarah Hackman William Phillips Supreet Kaur Sherri Cervantez William Kelly Josephine Taverna Source Type: research

Abstracts of Presentations at the Association of Clinical Scientists 143 < sup > rd < /sup > Meeting Louisville, KY May 11-14,2022
Conclusion: These assays are suitable for routine diagnostic. The UltraFast NextGenPCR is the fastest with average time (30mins), followed by Agilent (2 hrs) and MassArray (6hrs). Upon completion of this activity, participants should be able to examine, measure and compare results from different assays for SARS detection, evaluate and diagnose accurately, as well as being able to plan, organize and recommend a diagnostic procedure for diagnostic laboratory. Key words: SARS-CoV-2, RNA extraction, RT-PCR, limit of detection, quantification cycle, COVID-19, in vitro diagnostic tests, Agilent, Massarray, Ultrafast. [20] From t...
Source: Annals of Clinical and Laboratory Science - July 1, 2022 Category: Laboratory Medicine Source Type: research

Phase 2 trial of T-cell activation using MVI-816 and pembrolizumab in patients with metastatic, castration-resistant prostate cancer (mCRPC)
CONCLUSIONS: Findings here demonstrate that combining programmed cell death 1 blockade with MVI-816 is safe, can augment tumor-specific T cells, and can result in a favorable 6-month disease control rate. Correlative studies suggest T-cell activation by vaccination is critical to the mechanism of action of this combination. Future randomized clinical trials are needed to validate these findings.TRIAL REGISTRATION NUMBER: NCT02499835.PMID:35277461 | DOI:10.1136/jitc-2021-004198
Source: Cancer Control - March 12, 2022 Category: Cancer & Oncology Authors: Douglas G McNeel Jens C Eickhoff Ellen Wargowski Laura E Johnson Christos E Kyriakopoulos Hamid Emamekhoo Joshua M Lang Mary Jane Brennan Glenn Liu Source Type: research

Fight Aging! Newsletter, August 30th 2021
Fight Aging! publishes news and commentary relevant to the goal of ending all age-related disease, to be achieved by bringing the mechanisms of aging under the control of modern medicine. This weekly newsletter is sent to thousands of interested subscribers. To subscribe or unsubscribe from the newsletter, please visit: https://www.fightaging.org/newsletter/ Longevity Industry Consulting Services Reason, the founder of Fight Aging! and Repair Biotechnologies, offers strategic consulting services to investors, entrepreneurs, and others interested in the longevity industry and its complexities. To find out mo...
Source: Fight Aging! - August 29, 2021 Category: Research Authors: Reason Tags: Newsletters Source Type: blogs